Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
Biomea Fusion reported first quarter 2026 financial results highlighting progress in key clinical trials for its diabetes and obesity drug candidates, icovamenib and BMF-650. The company completed chronic toxicology studies supporting longer clinical dosing for icovamenib, reported positive topline data from a Phase II type 1 diabetes trial, and in…